cadenas
  • Innovative Therapies
    for Children with Cancer in Europe
  • Contact us

Solid Tumor

  • ITCC-061 EZH-102

    Solid Tumor

    A Phase 1 Study of EPZ-6438 (an EZH2 Inhibitor) in Pediatric Patients with Relapsed/Refractory INI1-Negative Tumors or Synovial Sarcomas

  • A Phase I/II Study of the Oral TRK Inhibitor LOXO 101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors

  • INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies

  • Pilot study of nivolumab in paediatric patients with hypermutant cancers

  • A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete...

  • Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or Durvalumab in Combination with Tremelimumab in Pediatric Patients with...

  • A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients (aged 6 months to 17 years) with Solid Tumours

  • PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB (RXDX-101) IN CHILDREN AND ADOLESCENTS WITH NO CURATIVE FIRST-LINE TREATMENT OPTION, RECURRENT OR REFRACTORY SOLID TUMORS...